SCHEMBL981123

SCHEMBL981123

Clc1cc(C2(Cc3ccccc3)CCN(Cc3ccccc3)C2)cc2cc[nH]c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CYP2D6 P10635 5/20 0.43
SLC6A2 P23975 4/20 0.43
SLC6A4 P31645 4/20 0.43
SLC6A3 Q01959 4/20 0.43
KCNH2 Q12809 1/20 0.43
NR3C1 P04150 2/20 0.42
TSHR P16473 2/20 0.40
CYP3A4 P08684 1/20 0.40
CCR3 P51677 1/20 0.39
OPRL1 P41146 1/20 0.37
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
POLB P06746 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
MAPK14 Q16539 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2800730 0.92 SLC6A2 (0.57) KMT2AKDM4ECYP2D6SLC6A2SLC6A4
SCHEMBL984260 0.83 SLC6A2 (0.63) KMT2AKDM4ECYP2D6SLC6A2SLC6A4
SCHEMBL984635 0.82 CYP2D6 (0.62) KMT2AKDM4ECYP2D6SLC6A2SLC6A4
SCHEMBL982050 0.82 SLC6A2 (0.64) KMT2AKDM4ECYP2D6SLC6A2SLC6A4
SCHEMBL985195 0.79 SLC6A2 (0.66) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL983580 0.78 SLC6A2 (0.60) KMT2AKDM4ECYP2D6SLC6A2SLC6A4
SCHEMBL980929 0.75 CYP2D6 (0.64) KMT2AKDM4ECYP2D6SLC6A2SLC6A4
SCHEMBL984198 0.73 CYP2D6 (0.64) KMT2AKDM4ECYP2D6SLC6A2SLC6A4
SCHEMBL984138 0.73 SLC6A2 (0.66) KMT2AKDM4ECYP2D6SLC6A2SLC6A4
SCHEMBL984578 0.72 NR3C1 (0.51) KMT2AKDM4ECYP2D6NR3C1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
EP-2257545-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 KMT2A 2106/4885KDM4E 680/4885CYP2D6 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.